DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205488
» See Plans and Pricing
NDA 205488 describes NATESTO, which is a drug marketed by Acerus and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the NATESTO profile page.
The generic ingredient in NATESTO is testosterone. There are sixty-nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
The generic ingredient in NATESTO is testosterone. There are sixty-nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for 205488
| Tradename: | NATESTO |
| Applicant: | Acerus |
| Ingredient: | testosterone |
| Patents: | 4 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 205488
| Mechanism of Action | Androgen Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 205488
Suppliers and Packaging for NDA: 205488
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NATESTO | testosterone | GEL, METERED;NASAL | 205488 | NDA | Acerus Pharmaceuticals Corporation | 42667-5511 | 42667-5511-1 | 1 APPLICATOR in 1 BOX (42667-5511-1) > 11 g in 1 APPLICATOR |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL, METERED;NASAL | Strength | 5.5MG/0.122GM ACTUATION | ||||
| Approval Date: | May 28, 2014 | TE: | RLD: | No | |||||
| Patent: | Start Trial | Patent Expiration: | Feb 4, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | Start Trial | Patent Expiration: | Feb 4, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | Start Trial | Patent Expiration: | Feb 4, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
